Accent Microcell, a prominent name in the world of cellulose-based pharmaceutical excipients, is gearing up for a significant move as it announces the opening of its Initial Public Offer (IPO) on December 8. The company, recognized for its role as a leading manufacturer and exporter, is set to make waves in the financial market. With the IPO priced between Rs 133–140 per share, Accent Microcell aims to raise approximately Rs 78.40 crores, paving the way for an exciting chapter in its journey.
The IPO Details:
The IPO journey kicks off with the Anchor portion on December 7, creating anticipation for investors. The public offer will be open for subscription until December 12. The lot price is fixed at 1,000 shares, making it accessible for a diverse range of investors. Accent Microcell has set its sights on listing with NSE Emerge, showcasing its commitment to broader market exposure.
A Glimpse into Accent Microcell’s Vision:
Apart from the financial endeavor, Accent Microcell is set to embark on a new project using the net proceeds from the offering. With Rs 54.39 crores earmarked for this venture, the company plans to establish a state-of-the-art plant in Navagam Kheda, Gujarat, India. This facility will focus on manufacturing essential pharmaceutical components, including Croscarmellose Sodium (CCS), Sodium Starch Glycolate (SSG), and Carboxymethylcellulose (CMC), with commercialization expected by April 2025.
Company’s Core Operations:
Accent Microcell’s core expertise lies in the production of Microcrystalline Cellulose (MCC), a versatile component widely used across pharmaceutical, nutraceutical, food, cosmetic, and various other industries. MCC serves multiple purposes, acting as a texturizer, anticaking agent, binder, lubricant, bulking agent, and diluent. In addition to MCC, the company manufactures other crucial excipients such as Croscarmellose Sodium (CCS) and Magnesium Stearate (MS).
As Accent Microcell steps into the IPO arena, it not only marks a significant financial milestone but also sets the stage for future growth and innovation. The company’s commitment to expanding its operations and venturing into new projects highlights its vision for sustained excellence. Investors and industry enthusiasts alike are eager to witness the outcome of this exciting journey, which holds the promise of shaping the landscape of cellulose-based pharmaceutical excipients. The curtains rise on December 8, ushering in a new chapter for Accent Microcell.
